---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-279715"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T02:53:55.056491+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Trevi prices $50M underwritten offering of 12.5M shares at $4.00 per share

## Summary
- Offering of 12.5M shares at $4.00/share; net proceeds ~$46.7M after underwriting discounts and expenses.
- Participants include Adage Capital, Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital, Vivo Capital.
- Expected to close on December 17, 2024, subject to customary conditions.
- Company developing Haduvio for chronic cough in IPF and refractory chronic cough.
- Leerink Partners, Stifel, and Oppenheimer are joint book-running managers.

## SEC filing metadata
- accession: 0001193125-24-279715
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312524279715/0001193125-24-279715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312524279715/d738809d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-279715
- JSON: https://secwatch.observer/filing/0001193125-24-279715.json
- Plain text: https://secwatch.observer/filing/0001193125-24-279715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.